Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Novartis AG (NVS) - free report >>
Pacira BioSciences, Inc. (PCRX) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis AG (NVS) - free report >>
Pacira BioSciences, Inc. (PCRX) - free report >>
Image: Bigstock
Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
Novartis Pharma AG (NVS - Free Report) announced positive results from a head-to-head study, FLAME, on Ultibro Breezhaler at the 2016 European Respiratory Society (ERS) International Congress.
The randomized, double-blinded, double-dummy, parallel-group, non-inferiority, active-controlled, 52-week study affirmed that Ultibro Breezhaler is a more effective option for patients at the risk of chronic obstructive pulmonary disease (COPD) flare-ups (exacerbations) than Seretide.
Results also showed that once-daily Ultibro Breezhaler 110/50 mcg led to consistent reductions in the rate of all exacerbations. Earlier this year, the study showed that Ultibro Breezhaler was superior to Seretide in reducing exacerbations and improving lung function.
NOVARTIS AG-ADR Price
NOVARTIS AG-ADR Price | NOVARTIS AG-ADR Quote
We note that Ultibro Breezhaler is approved as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD.
Sales from the COPD portfolio came in at $322 million in the first half of 2016, up from $283 million in the year-ago period. Novartis’ portfolio currently comprises Ultibro Breezhaler, Seebri Breezhaler and Onbrez Breezhaler/Arcapta Neohaler, which are all approved maintenance treatments for COPD. Approximately 210 million people suffer from COPD, making it the third leading cause of death and underscoring the need for better treatments.
We expect investors to keep an eye on an approval of new drugs and label expansion of existing ones at Novartis as the company has been facing stiff generic competition for some of its key drugs like Diovan and Gleevec.
Novartis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , Corcept Therapeutics Incorporated (CORT - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All of these stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>